AR121299A1 - Inhibidores heterocíclicos de pad4 - Google Patents
Inhibidores heterocíclicos de pad4Info
- Publication number
- AR121299A1 AR121299A1 ARP210100336A ARP210100336A AR121299A1 AR 121299 A1 AR121299 A1 AR 121299A1 AR P210100336 A ARP210100336 A AR P210100336A AR P210100336 A ARP210100336 A AR P210100336A AR 121299 A1 AR121299 A1 AR 121299A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- independently selected
- alkyl
- crdrd
- heterocyclyl
- Prior art date
Links
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 title abstract 2
- 101150094373 Padi4 gene Proteins 0.000 title abstract 2
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 101150105130 RORB gene Proteins 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- -1 - NRaC(=O)ORb Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Luminescent Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041006146 | 2020-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121299A1 true AR121299A1 (es) | 2022-05-04 |
Family
ID=74856949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100336A AR121299A1 (es) | 2020-02-12 | 2021-02-10 | Inhibidores heterocíclicos de pad4 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12473304B2 (https=) |
| EP (1) | EP4103559B1 (https=) |
| JP (1) | JP7711075B2 (https=) |
| KR (1) | KR20220140795A (https=) |
| CN (1) | CN115348961B (https=) |
| AR (1) | AR121299A1 (https=) |
| AU (1) | AU2021219710A1 (https=) |
| BR (1) | BR112022015792A2 (https=) |
| CA (1) | CA3167753A1 (https=) |
| CL (1) | CL2022002148A1 (https=) |
| CO (1) | CO2022011388A2 (https=) |
| IL (1) | IL295506A (https=) |
| MX (1) | MX2022009874A (https=) |
| PE (1) | PE20230679A1 (https=) |
| TW (1) | TW202140477A (https=) |
| WO (1) | WO2021163254A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2021158840A1 (en) | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Macrocyclic pad4 inhibitors useful as immunosuppressant |
| TW202140477A (zh) | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環ｐａｄ４抑制劑 |
| WO2021222353A1 (en) | 2020-04-30 | 2021-11-04 | Gilead Sciences, Inc. | Macrocyclic inhibitors of peptidylarginine deiminases |
| TW202233174A (zh) | 2020-12-22 | 2022-09-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
| WO2022140390A1 (en) | 2020-12-22 | 2022-06-30 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
| KR20260041867A (ko) | 2023-07-21 | 2026-03-27 | 브리스톨-마이어스 스큅 컴퍼니 | Pad4 조정제의 시트룰린화 및 활성을 평가하는 방법 |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60007310D1 (de) | 1999-06-04 | 2004-01-29 | Elan Pharma Int Ltd | Zusammensetzungen und methoden zur verhinderung des zelltods |
| MX2007010371A (es) | 2005-02-25 | 2008-01-11 | Tetralogic Pharmaceuticals | Inhibidores dimericos iap. |
| US7825154B2 (en) | 2005-08-12 | 2010-11-02 | The United States Of America As Represented By The Secretary Of The Army | Small molecule inhibitors of botulinum neurotoxins |
| CN101466670B (zh) | 2006-04-07 | 2013-04-17 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| US7842713B2 (en) | 2006-04-20 | 2010-11-30 | Pfizer Inc | Fused phenyl amido heterocyclic compounds |
| EP2120952A4 (en) | 2007-01-15 | 2011-09-21 | Us Of America As Represented By The Secretary Of The Army On Behalf Of The U S Army Res Inst Of Infe | ANTIVIRAL COMPOUNDS AND METHODS OF USE |
| US20110052562A1 (en) | 2007-12-19 | 2011-03-03 | The Scripps Research Institute | Benzimidazoles and analogs as rho kinase inhibitors |
| JP2010013386A (ja) | 2008-07-02 | 2010-01-21 | Fujifilm Corp | 染毛剤、染毛方法およびその製造方法 |
| WO2013040528A1 (en) | 2011-09-16 | 2013-03-21 | Microbiotix, Inc. | Antimicrobial compounds |
| WO2013052263A2 (en) | 2011-09-16 | 2013-04-11 | Microbiotix, Inc. | Antifungal compounds |
| KR101916443B1 (ko) * | 2012-07-26 | 2018-11-08 | 글락소 그룹 리미티드 | Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸 |
| CN103030627B (zh) | 2013-01-07 | 2017-11-10 | 中国科学院上海有机化学研究所 | 一种噻吩环/呋喃环‑杂芳环结构的合成方法 |
| WO2014177593A1 (en) | 2013-04-29 | 2014-11-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Amorfrutin analogs as ppargamma-modulators |
| WO2016004513A1 (en) | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| KR101501091B1 (ko) | 2014-09-04 | 2015-03-10 | 주식회사 해치엠엠에이 | 도포용 바닥재의 미끄럼방지 요철형성용 롤러장치 |
| KR20180005250A (ko) * | 2015-05-21 | 2018-01-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Pad4 억제제로서의 벤조이미다졸 유도체 |
| US20180312493A1 (en) | 2015-11-04 | 2018-11-01 | Simon Fraser University | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor |
| AR107032A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| AR107030A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
| US10654814B2 (en) * | 2015-12-22 | 2020-05-19 | Kancera Ab | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity |
| CA3015482A1 (en) | 2016-02-23 | 2017-08-31 | Padlock Therapeutics, Inc. | Heteroaryl inhibitors of pad4 |
| WO2018022897A1 (en) | 2016-07-27 | 2018-02-01 | Padlock Therapeutics, Inc. | Covalent inhibitors of pad4 |
| US11026937B2 (en) | 2016-09-12 | 2021-06-08 | Padlock Therapeutics, Inc. | Heteroaryl inhibitors of PAD4 |
| JP2018140974A (ja) | 2017-02-28 | 2018-09-13 | 国立大学法人 奈良先端科学技術大学院大学 | 放射線検出方法及び放射線検出器並びに放射線検出に用いられる新規化合物 |
| CN108689942B (zh) | 2017-04-11 | 2023-06-09 | 广东东阳光药业有限公司 | 含氮双环化合物及其制备方法和用途 |
| JP7311228B2 (ja) * | 2017-06-30 | 2023-07-19 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 |
| ES2932627T3 (es) | 2017-08-22 | 2023-01-23 | Bayer Ag | Derivados heterocíclicos como pesticidas |
| AU2018352142B2 (en) * | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| MX2021001565A (es) | 2018-08-08 | 2021-04-19 | Bristol Myers Squibb Co | Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad). |
| MX2021001471A (es) | 2018-08-08 | 2021-04-28 | Bristol Myers Squibb Co | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). |
| JP7447080B2 (ja) | 2018-08-08 | 2024-03-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐａｄ４阻害剤としての置換チエノピロール |
| US20220348562A1 (en) | 2018-08-08 | 2022-11-03 | Bristol-Myers Squibb Company | Benzimidazole inhibitors of pad enzymes |
| WO2021158840A1 (en) | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Macrocyclic pad4 inhibitors useful as immunosuppressant |
| TW202140477A (zh) | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環ｐａｄ４抑制劑 |
-
2021
- 2021-02-09 TW TW110105125A patent/TW202140477A/zh unknown
- 2021-02-10 AR ARP210100336A patent/AR121299A1/es not_active Application Discontinuation
- 2021-02-11 US US17/799,028 patent/US12473304B2/en active Active
- 2021-02-11 CN CN202180025726.9A patent/CN115348961B/zh active Active
- 2021-02-11 MX MX2022009874A patent/MX2022009874A/es unknown
- 2021-02-11 CA CA3167753A patent/CA3167753A1/en active Pending
- 2021-02-11 IL IL295506A patent/IL295506A/en unknown
- 2021-02-11 EP EP21709851.6A patent/EP4103559B1/en active Active
- 2021-02-11 PE PE2022001712A patent/PE20230679A1/es unknown
- 2021-02-11 BR BR112022015792A patent/BR112022015792A2/pt not_active Application Discontinuation
- 2021-02-11 KR KR1020227031398A patent/KR20220140795A/ko active Pending
- 2021-02-11 AU AU2021219710A patent/AU2021219710A1/en not_active Abandoned
- 2021-02-11 JP JP2022548707A patent/JP7711075B2/ja active Active
- 2021-02-11 WO PCT/US2021/017554 patent/WO2021163254A1/en not_active Ceased
-
2022
- 2022-08-10 CL CL2022002148A patent/CL2022002148A1/es unknown
- 2022-08-12 CO CONC2022/0011388A patent/CO2022011388A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021219710A1 (en) | 2022-10-06 |
| US12473304B2 (en) | 2025-11-18 |
| EP4103559B1 (en) | 2026-03-04 |
| JP2023515780A (ja) | 2023-04-14 |
| US20230167131A1 (en) | 2023-06-01 |
| KR20220140795A (ko) | 2022-10-18 |
| EP4103559A1 (en) | 2022-12-21 |
| PE20230679A1 (es) | 2023-04-21 |
| CN115348961B (zh) | 2025-03-04 |
| CA3167753A1 (en) | 2021-08-19 |
| JP7711075B2 (ja) | 2025-07-22 |
| TW202140477A (zh) | 2021-11-01 |
| MX2022009874A (es) | 2022-08-22 |
| BR112022015792A2 (pt) | 2022-10-11 |
| WO2021163254A1 (en) | 2021-08-19 |
| IL295506A (en) | 2022-10-01 |
| CN115348961A (zh) | 2022-11-15 |
| CO2022011388A2 (es) | 2022-08-30 |
| CL2022002148A1 (es) | 2023-02-24 |
| EP4103559C0 (en) | 2026-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121299A1 (es) | Inhibidores heterocíclicos de pad4 | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| AR115920A1 (es) | Inhibidores tipo indol y azaindol de enzimas pad | |
| AR108838A1 (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa | |
| AR103990A1 (es) | Ureas cíclicas como inhibidoras de rock | |
| AR107714A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| CN111601797A (zh) | 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
| AR094929A1 (es) | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 | |
| AR119971A1 (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
| AR103566A1 (es) | Compuestos derivados de heteroarilo y heterociclo condensados | |
| AR119728A1 (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2 | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR088748A1 (es) | Macrociclos como inhibidores del factor xia | |
| AR088258A1 (es) | Inhibidores de la pde10 de azetidina 1,3-sustituida | |
| AR103598A1 (es) | Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac | |
| AR082218A1 (es) | Derivados de arilamida que tienen propiedades antiandrogenicas y proceso de preparacion | |
| JP2021535213A5 (https=) | ||
| JP2018524406A5 (https=) | ||
| AR115065A1 (es) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina | |
| PE20200756A1 (es) | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica | |
| AR121674A1 (es) | Amidas heterocíclicas como inhibidoras del receptor de tirosina quinasa de tipo iii | |
| AR121341A1 (es) | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática | |
| JP2024533787A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |